Month: November 2024

The field of second-line treatment for advanced gastric cancer is a current focal point in oncology research. On February 6, 2024, during the ASCO Plenary Series, Dr. Ruihua Xu from Sun Yat-sen University Cancer Center presented findings from the FRUTIGA study (NCT03223376), a phase III trial conducted in China evaluating the efficacy of fruquintinib combined with paclitaxel for second-line treatment in advanced gastric cancer. The study offers an additional treatment option for advanced gastric cancer. Oncology Frontier highlighted perspectives from Dr. Ruihua Xu and Dr. Florian Lordick, Director of the University Cancer Center Leipzig, on the significance of FRUTIGA. Here’s a summary of the discussion.

On October 18, 2024, the 18th National Breast Cancer Conference and the 19th Shanghai International Breast Cancer Forum grandly opened, gathering significant global advancements in breast cancer. In the era following CDK4/6 inhibitors for hormone receptor-positive (HR+) breast cancer, targeted endocrine therapies based on the PIK3CA/AKT1/PTEN pathway have brought new hope to patients. At this conference, Dr. Virginia Kaklamani from The University of Texas MD Anderson Cancer Center shared important insights on the progress of treating HR+ metastatic breast cancer and discussed post-CDK4/6 inhibitor strategies and clinical practice experiences for HR+ advanced breast cancer in the "Viewpoint · SIBCS Special" column of Oncology Horizon.

For patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), dual inhibition of EGFR and MET may be the most effective strategy after disease progression on osimertinib, particularly for patients with MET gene amplification (METamp). Dr. Benjamin Besse, Dr. Lodovica Zullo, and Dr. Jordi Remon from the Gustave Roussy Institute analyze therapeutic strategies for METamp-driven resistance following osimertinib treatment in this article.

Breast reconstruction surgery offers hope for patients to regain confidence and beauty in the field of breast cancer treatment. With advances in medical technology, implant-based breast reconstruction has become a mainstream choice. However, complications related to implants remain a key concern for both surgeons and patients. At the 16th Shanghai Breast Reconstruction Conference, Dr. Benlong Yang from the Breast Surgery Department of Fudan University Shanghai Cancer Center led a session discussing "Implant Complications." Following the event, Oncology Frontier interviewed Dr. Yang to delve into key issues surrounding implant reconstruction.

From October 17-19, 2024, the 18th International Liver Cancer Association (ILCA) Annual Conference, a prestigious academic event in the global liver cancer field, took place in Toronto, Canada. Liver cancer experts from around the world convened to discuss hot topics and the latest advancements in the basics and clinical aspects of liver cancer. This conference featured the latest research findings from scholars in the global liver cancer field. This article specially compiled the significant clinical research in the field of liver cancer treatment presented at this ILCA conference for the exchange and learning of peers. Our special correspondent from "Oncology Frontier" attended the conference on-site for in-depth coverage, and more exciting content was expected to be shared!

From September 25 to 29, 2024, the 27th National Conference on Clinical Oncology and the 2024 CSCO Annual Meeting, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, was held in Xiamen. Themed "Patient-Centered, Shared Future," the conference attracted tens of thousands of oncology experts and pharmaceutical elites from home and abroad to discuss the latest advancements in cancer prevention and treatment, cutting-edge technologies, and future trends. During the conference, Oncology Frontier had the honor of interviewing Dr. Shukui Qin, one of the founders and Vice President of CSCO. In this interview, Professor Qin reflected on CSCO’s remarkable journey since its founding in 1997, including its development through three major phases: preparation, institutionalization, and cultural growth. Supported by the Party and the government, CSCO has actively promoted five core tasks: continuing medical education in clinical oncology, academic exchanges, clinical research, expert consensus formulation, and patient services, achieving remarkable progress. Professor Qin highlighted the extraordinary progress in primary liver cancer treatment, from stagnation to breakthroughs, emphasizing CSCO’s ongoing efforts to foster multidisciplinary collaboration, strengthen basic and translational research, and explore "combination strategies" to significantly improve the survival rates of liver cancer patients.

During the 2024 CACA Integrated Esophageal Cancer Academic Conference, Dr. Shaoming Wang from the Cancer Hospital Chinese Academy of Medical Sciences gave an in-depth explanation of research progress on the burden of upper gastrointestinal cancer. During the conference, Oncology Frontier had the pleasure of interviewing Professor Wang to further explore his team’s latest research findings on the global lifetime risk of gastrointestinal cancer.